Pegtarviliase (TVT-058)

About Travere Therapeutics

Travere Therapeutics is a San Diego-based biopharma leader dedicated to rare diseases, particularly in nephrology and metabolism. The company has successfully transitioned to commercial operations with a fully approved therapy for IgA nephropathy (IgAN) and a late-stage pipeline targeting conditions like focal segmental glomerulosclerosis (FSGS) and classical homocystinuria (HCU). Its strategy leverages deep community engagement and scientific expertise to navigate complex development pathways and establish new standards of care in niche markets.

Therapeutic Areas